The future of vitamin D analogs

Frontiers in Physiology

Volumn 5 APR, Issue , 2014, Pages

  Leyssens, Carlien ^a   Verlinden, Lieve ^a   Verstuyf, Annemieke ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Analogs; Cancer; Pleiotropic effects; Vitamin D

Indexed keywords

16 ENE 23 YNE 1ALPHA,25 DIHYDROXYVITAMIN D3; 19 NOR 14,20 BISEPI 23 YNE 1ALPHA,25 DIHYDROXYVITAMIN D3; 19 NOR 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXYVITAMIN D3; 1ALPHA,25 DIHYDROXYVITAMIN D3 3 BROMOACETATE; 22 ENE 26,27 DEHYDRO 1ALPHA,25 DIHYDROXYVITAMIN D3; 22 OXACALCITRIOL; 4 HYDROXY 4 METHYLPENTYL 23 YNE 26,27 HEXAFLUORO 19 NOR 1ALPHA,25 DIHYDROXYVITAMIN D3; ALFACALCIDOL; ALPHA INTERFERON; BETAMETHASONE DIPROPIONATE; BXL 01 0126; CALCIPOTRIOL; CALCITRIOL; DICLOFENAC; DOCETAXEL; DOXERCALCIFEROL; EDIROL; EFLORNITHINE; ELDECALCITOL; FALECALCITRIOL; FLUOROURACIL; ILX 23 7553; INECALCITOL; IRINOTECAN; LEXACALCITOL; MART 10; OXALIPLATIN; PARICALCITOL; PLACEBO; PRI 2205; SEOCALCITOL; SORILUX; TACALCITOL; TAXANE DERIVATIVE; TX 527; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BILE DUCT CARCINOMA; BONE DENSITY; BREAST CANCER; BREAST METASTASIS; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CHRONIC KIDNEY DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COLORECTAL TUMOR; DRUG POTENTIATION; DRUG STRUCTURE; END STAGE RENAL DISEASE; GLIOBLASTOMA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG CANCER; MIGRATION INHIBITION; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PANCREAS CANCER; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PSORIASIS; REVIEW; SECONDARY HYPERPARATHYROIDISM; SKIN METASTASIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR CELL; TUMOR XENOGRAFT; VITAMIN D RESPONSIVE ELEMENT;

EID: 84901062286     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00122     Document Type: Review

References (110)

1. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129, 832-837. doi: 10.1210/endo-129-2-832
2. Akhter, J., Chen, X., Bowrey, P., Bolton, E. J., and Morris, D. L. (1997). Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 40, 317-321. doi: 10.1007/BF02050422
3. 2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch. Ophthalmol. 122, 1365-1369. doi: 10.1001/archopht.122.9.1365
4. Albert, D. M., Kumar, A., Strugnell, S. A., Darjatmoko, S. R., Lokken, J. M., Lindstrom, M. J., et al. (2004b). Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch. Ophthalmol. 122, 1357-1362. doi: 10.1001/archopht.122.9.1357
5. Attia, S., Eickhoff, J., Wilding, G., McNeel, D., Blank, J., Ahuja, H., et al. (2008). Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14, 2437-2443. doi: 10.1158/1078-0432.CCR-07-4274
6. Bae, S., Yalamarti, B., Ke, Q., Choudhury, S., Yu, H., Karumanchi, S. A., et al. (2011). Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc. Res. 91, 632-639. doi: 10.1093/cvr/cvr133
7. Baeke, F., Korf, H., Overbergh, L., Verstuyf, A., Thorrez, L., Van Lommel, L., et al. (2011). The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J. Immunol. 186, 132-142. doi: 10.4049/jimmunol.1000695
8. 3 analogs, in-vitro and in-vivo studies. Invest. New Drugs 31, 247-255. doi: 10.1007/s10637-012-9839-1
9. Bhatia, V., Saini, M. K., Shen, X., Bi, L. X., Qiu, S., Weigel, N. L., et al. (2009). EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8, 1787-1798. doi: 10.1158/1535-7163.MCT-09-0064
10. Blutt, S. E., Polek, T. C., Stewart, L. V., Kattan, M. W., and Weigel, N. L. (2000). A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 60, 779-782.
11. Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J. C., Ford, H. T., et al. (1991). Topical calcipotriol treatment in advanced breast cancer. Lancet 337, 701-702. doi: 10.1016/0140-6736(91)90280-3
12. Chiang, K. C., Yeh, C. N., Hsu, J. T., Yeh, T. S., Jan, Y. Y., Wu, C. T., et al. (2013). Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle 12, 1316-1325. doi: 10.4161/cc.24445
13. Coburn, J. W., Maung, H. M., Elangovan, L., Germain, M. J., Lindberg, J. S., Sprague, S. M., et al. (2004). Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. 43, 877-890. doi: 10.1053/j.ajkd.2004.01.012
14. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108, 1083-1086. doi: 10.1210/endo-108-3-1083
15. Coyne, D., Acharya, M., Qiu, P., Abboud, H., Batlle, D., Rosansky, S., et al. (2006). Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 47, 263-276. doi: 10.1053/j.ajkd.2005.10.007
16. Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K. J., Lofts, F. J., et al. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89, 252-257. doi: 10.1038/sj.bjc.6601104
17. 3. J. Cell. Biochem. 63, 199-206. doi: 10.1002/(SICI)1097-4644(19961101)63:2<199::AID-JCB7>3.0.CO;2-T
18. Dilworth, F. J., Williams, G. R., Kissmeyer, A. M., Nielsen, J. L., Binderup, E., Calverley, M. J., et al. (1997). The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 138, 5485-5496. doi: 10.1210/en.138.12.5485
19. Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., et al. (2013). A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601-613. doi: 10.1016/j.cell.2013.03.028
20. Eelen, G., Gysemans, C., Verlinden, L., Vanoirbeek, E., De Clercq, P., Van Haver, D., et al. (2007). Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr. Med. Chem. 14, 1893-1910. doi: 10.2174/092986707781058823
21. 3 analogs stabilize helix 12 of the vitamin D receptor. Chem. Biol. 15, 1029-1034. doi: 10.1016/j.chembiol.2008.08.008
22. Eelen, G., Verlinden, L., Rochel, N., Claessens, F., De Clercq, P., Vandewalle, M., et al. (2005). Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 67, 1566-1573. doi: 10.1124/mol.104.008730
23. El Abdaimi, K., Dion, N., Papavasiliou, V., Cardinal, P. E., Binderup, L., Goltzman, D., et al. (2000). The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 60, 4412-4418.
24. Evans, T. R., Colston, K. W., Lofts, F. J., Cunningham, D., Anthoney, D. A., Gogas, H., et al. (2002). A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 86, 680-685. doi: 10.1038/sj.bjc.6600162
25. Fichera, A., Little, N., Dougherty, U., Mustafi, R., Cerda, S., Li, Y. C., et al. (2007). A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J. Surg. Res. 142, 239-245. doi: 10.1016/j.jss.2007.02.038
26. Flanagan, L., Packman, K., Juba, B., O'Neill, S., Tenniswood, M., and Welsh, J. (2003). Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol. 84, 181-192. doi: 10.1016/S0960-0760(03)00028-1
27. 2 in patients with clinically localized prostate cancer and high grade pin. Prostate 73, 970-978. doi: 10.1002/pros.22644
28. Ghous, Z., Akhter, J., Pourgholami, M. H., and Morris, D. L. (2008). Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 28, 3757-3761.
29. 3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 151, 23-31. doi: 10.1210/en.2009-0650
30. 3 analog. J. Steroid Biochem. Mol. Biol. 89-90, 443-448. doi: 10.1016/j.jsbmb.2004.03.039
31. 2 in a retinoblastoma xenograft model. Arch. Ophthalmol. 120, 607-612. doi: 10.1001/archopht.120.5.607
32. Gulliford, T., English, J., Colston, K. W., Menday, P., Moller, S., and Coombes, R. C. (1998). A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 78, 6-13. doi: 10.1038/bjc.1998.434
33. Hagino, H., Takano, T., Fukunaga, M., Shiraki, M., Nakamura, T., and Matsumoto, T. (2013). Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J. Bone Miner. Metab. 31, 183-189. doi: 10.1007/s00774-012-0397-6
34. Hamdy, N. A., Kanis, J. A., Beneton, M. N., Brown, C. B., Juttmann, J. R., Jordans, J. G., et al. (1995). Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310, 358-363. doi: 10.1136/bmj.310.6976.358
35. Hansen, C. M., and Maenpaa, P. H. (1997). EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem. Pharmacol. 54, 1173-1179. doi: 10.1016/S0006-2952(97)00181-0
36. 3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res. 21, 321-324.
37. Harada, S., Mizoguchi, T., Kobayashi, Y., Nakamichi, Y., Takeda, S., Sakai, S., et al. (2012). Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J. Bone Miner. Res. 27, 461-473. doi: 10.1002/jbmr.555
38. Hybrigenics. (2014). Inecalcitol. [Internet] Paris, France: Hybrigenics [cited 2014 29/01]. Available online at: http://www.hybrigenics.com/contents/pharma-1/inecalcitol-1
39. 3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res. Treat. 22, 133-140. doi: 10.1007/BF01833343
40. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer 81, 730-733. doi: 10.1002/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO;2-Q
41. Ito, M., Nakamura, T., Fukunaga, M., Shiraki, M., and Matsumoto, T. (2011). Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 49, 328-334. doi: 10.1016/j.bone.2011.05.002
42. 3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Invest. New Drugs 29, 1420-1425. doi: 10.1007/s10637-010-9492-5
43. James, S. Y., Mercer, E., Brady, M., Binderup, L., and Colston, K. W. (1998). EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 125, 953-962. doi: 10.1038/sj.bjp.0702103
44. Jensen, S. S., Madsen, M. W., Lukas, J., Binderup, L., and Bartek, J. (2001). Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 15, 1370-1380. doi: 10.1210/mend.15.8.0673
45. Jones, G. (1997). "Analog metabolism," in Vitamin D. 1st Edn., ed D. Feldman (San Diego, CA: Academic Press), 973-994.
46. 3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J. Steroid Biochem. Mol. Biol. 97, 173-177. doi: 10.1016/j.jsbmb.2005.06.021
47. 3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110, 1605-1613. doi: 10.1053/gast.1996.v110.pm8613068
48. Kissmeyer, A. M., Binderup, E., Binderup, L., Mork Hansen, C., Andersen, N. R., Makin, H. L., et al. (1997). Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol. 53, 1087-1097. doi: 10.1016/S0006-2952(96)00816-7
49. Kriebitzsch, C., Verlinden, L., Eelen, G., Tan, B. K., Van Camp, M., Bouillon, R., et al. (2009). The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells-a microarray approach. Anticancer Res. 29, 3471-3483.
50. 3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev. Res. (Phila.) 3, 1596-1607. doi: 10.1158/1940-6207.CAPR-10-0122
51. Lawrence, J. A., Akman, S. A., Melin, S. A., Case, L. D., and Schwartz, G. G. (2013). Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol. Ther. 14, 476-480. doi: 10.4161/cbt.24350
52. Lee, H. J., Paul, S., Atalla, N., Thomas, P. E., Lin, X., Yang, I., et al. (2008). Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev. Res. (Phila.) 1, 476-484. doi: 10.1158/1940-6207.CAPR-08-0084
53. Lee, H. J., So, J. Y., DeCastro, A., Smolarek, A., Paul, S., Maehr, H., et al. (2010). Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J. Steroid Biochem. Mol. Biol. 121, 408-412. doi: 10.1016/j.jsbmb.2010.03.053
54. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16, 1243-1256. doi: 10.1210/mend.16.6.0874
55. Liska, J., Macejova, D., Ondkova, S., and Brtko, J. (2012). Morphology of 1-methyl-1-nitrosourea induced rat mammary tumours after treatment with precursor of phytanic acid or its combination with vitamin D analogue. Endocr. Regul. 46, 21-26. doi: 10.4149/endo_2012_021
56. Liu, G., Oettel, K., Ripple, G., Staab, M. J., Horvath, D., Alberti, D., et al. (2002). Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res. 8, 2820-2827.
57. Liu, G., Wilding, G., Staab, M. J., Horvath, D., Miller, K., Dresen, A., et al. (2003). Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. 9, 4077-4083.
58. Liu, Y. Y., Nguyen, C., Ali Gardezi, S. A., Schnirer, I., and Peleg, S. (2001). Differential regulation of heterodimerization by 1alpha,25-dihydroxyvitamin D(3) and its 20-epi analog. Steroids 66, 203-212. doi: 10.1016/S0039-128X(00)00151-3
59. Liu, Y. Y., Nguyen, C., and Peleg, S. (2000). Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol. Endocrinol. 14, 1776-1787. doi: 10.1210/mend.14.11.0560
60. Lokeshwar, B. L., Schwartz, G. G., Selzer, M. G., Burnstein, K. L., Zhuang, S. H., Block, N. L., et al. (1999). Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8, 241-248.
61. Lundqvist, J., Hansen, S. K., and Lykkesfeldt, A. E. (2013). Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim. Biophys. Acta 1833, 40-47. doi: 10.1016/j.bbamcr.2012.10.012
62. Ma, Y., Yu, W. D., Hidalgo, A. A., Luo, W., Delansorne, R., Johnson, C. S., et al. (2013). Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12, 743-752. doi: 10.4161/cc.23846
63. Macejova, D., Ondkova, S., Jakubikova, L., Mlynarcikova, A., Scsukova, S., Liska, J., et al. (2011). MNU-induced mammary gland carcinogenesis: chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol. Lett. 207, 60-72. doi: 10.1016/j.toxlet.2011.07.029
64. 3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone 49, 605-612. doi: 10.1016/j.bone.2011.07.011
65. Milczarek, M., Psurski, M., Kutner, A., and Wietrzyk, J. (2013a). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13:294. doi: 10.1186/1471-2407-13-294
66. Milczarek, M., Rosinska, S., Psurski, M., Maciejewska, M., Kutner, A., and Wietrzyk, J. (2013b). Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 33, 433-444.
67. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am. J. Hematol. 38, 67-68. doi: 10.1002/ajh.2830380112
68. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26, 1044-1054. doi: 10.1093/carcin/bgi049
69. 3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 90, 607-616. doi: 10.1046/j.1464-410X.2002.02964.x
70. 3 for Japanese patients with metastatic renal cell carcinoma. Int. J. Urol. 15, 794-799. doi: 10.1111/j.1442-2042.2008.02086.x
71. O'Brien, M. E., Talbot, D., Maclennan, K., and Smith, I. E. (1993). Inefficacy of calcipotriol in skin metastases from breast cancer. Lancet 342, 994. doi: 10.1016/0140-6736(93)92042-R
72. Okamoto, R., Delansorne, R., Wakimoto, N., Doan, N. B., Akagi, T., Shen, M., et al. (2012). Inecalcitol, an analog of 1alpha,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int. J. Cancer 130, 2464-2473. doi: 10.1002/ijc.26279
73. 3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. Int. J. Cancer 134, 207-217. doi: 10.1002/ijc.28328
74. 3. J. Nutr. Sci. Vitaminol. (Tokyo) 35, 529-533. doi: 10.3177/jnsv.35.529
75. 3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 163, 1444-1449. doi: 10.1016/0006-291X(89)91140-6
76. Park, M. R., Lee, J. H., Park, M. S., Hwang, J. E., Shim, H. J., Cho, S. H., et al. (2012). Suppressive effect of 19-nor-1alpha-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model. J. Korean Med. Sci. 27, 1037-1043. doi: 10.3346/jkms.2012.27.9.1037
77. Perez-Stable, C. M., Schwartz, G. G., Farinas, A., Finegold, M., Binderup, L., Howard, G. A., et al. (2002). The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol. Biomarkers Prev. 11, 555-563.
78. Petrini, M., Caracciolo, F., Corini, M., Valentini, P., Sabbatini, A. R., and Grassi, B. (1991). Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. Haematologica 76, 200-203.
79. Pommergaard, H. C., Burcharth, J., Rosenberg, J., and Raskov, H. (2013). Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res. 33, 3033-3039.
80. 3 analogue EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 93, 745-753. doi: 10.1093/jnci/93.10.745
81. Quack, M., and Carlberg, C. (1999). Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol. Pharmacol. 55, 1077-1087. doi: 10.1124/mol.55.6.1077
82. Raina, V., Cunningham, D., Gilchrist, N., and Soukop, M. (1991). Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br. J. Cancer 63, 463-465. doi: 10.1038/bjc.1991.108
83. 3 on metastasis of rat ascites hepatoma K-231. Br. J. Cancer 50, 123-125. doi: 10.1038/bjc.1984.148
84. Schwartz, G. G., Eads, D., Naczki, C., Northrup, S., Chen, T., and Koumenis, C. (2008). 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7, 430-436. doi: 10.4161/cbt.7.3.5418
85. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. 11(24 Pt 1), 8680-8685. doi: 10.1158/1078-0432.CCR-05-1237
86. 3 analogs. Arch. Biochem. Biophys. 465, 443-451. doi: 10.1016/j.abb.2007.06.015
87. 3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. Cancer 116, 5535-5543. doi: 10.1002/cncr.25478
88. Shalhoub, V., Shatzen, E. M., Ward, S. C., Young, J. I., Boedigheimer, M., Twehues, L., et al. (2010). Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J. Cell. Biochem. 111, 911-921. doi: 10.1002/jcb.22779
89. Shankar, V. N., Dilworth, F. J., Makin, H. L., Schroeder, N. J., Trafford, D. J., Kissmeyer, A. M., et al. (1997). Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem. Pharmacol. 53, 783-793. doi: 10.1016/S0006-2952(96)00815-5
90. Shinaberger, C. S., Kopple, J. D., Kovesdy, C. P., McAllister, C. J., van Wyck, D., Greenland, S., et al. (2008). Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1769-1776. doi: 10.2215/CJN.01760408
91. So, J. Y., Lee, H. J., Smolarek, A. K., Paul, S., Wang, C. X., Maehr, H., et al. (2011). A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol. Pharmacol. 79, 360-367. doi: 10.1124/mol.110.068403
92. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 9, 2350-2356.
93. Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., and Thadhani, R. (2003). Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349, 446-456. doi: 10.1056/NEJMoa022536
94. Tentori, F., Hunt, W. C., Stidley, C. A., Rohrscheib, M. R., Bedrick, E. J., Meyer, K. B., et al. (2006). Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858-1865. doi: 10.1038/sj.ki.5001868
95. Trouillas, P., Honnorat, J., Bret, P., Jouvet, A., and Gerard, J. P. (2001). Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J. Neurooncol. 51, 57-66. doi: 10.1023/A:1006437003352
96. Uchiyama, Y., Higuchi, Y., Takeda, S., Masaki, T., Shira-Ishi, A., Sato, K., et al. (2002). ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30, 582-588. doi: 10.1016/S8756-3282(02)00682-8
97. Valrance, M. E., Brunet, A. H., and Welsh, J. (2007). Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 148, 4887-4894. doi: 10.1210/en.2007-0267
98. 3 analog KH1060. Proc. Natl. Acad. Sci. U.S.A. 93, 10685-10690. doi: 10.1073/pnas.93.20.10685
99. van Ginkel, P. R., Yang, W., Marcet, M. M., Chow, C. C., Kulkarni, A. D., Darjatmoko, S., et al. (2007). 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J. Neurooncol. 85, 255-262. doi: 10.1007/s11060-007-9418-z
100. 3 or a 17-methyl-D-ring analog. Anticancer Res. 29, 3585-3590.
101. 3 analog, EB1089. Endocrinology 139, 2102-2110. doi: 10.1210/en.139.4.2102
102. 3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res. 23, 283-289.
103. Wietrzyk, J., Nevozhay, D., Filip, B., Milczarek, M., and Kutner, A. (2007). The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 27, 3387-3398.
104. Wietrzyk, J., Nevozhay, D., Milczarek, M., Filip, B., and Kutner, A. (2008). Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother. Pharmacol. 62, 787-797. doi: 10.1007/s00280-007-0666-6
105. 3 (PRI-2191). Steroids 69, 629-635. doi: 10.1016/j.steroids.2004.05.015
106. Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X., and Kroeger, P. E. (2007). VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell. Biochem. 100, 1395-1405. doi: 10.1002/jcb.21133
107. 3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J. Biol. Chem. 278, 31756-31765. doi: 10.1074/jbc.M304737200
108. 3 analog, HY-11, with low potential to cause hypercalcemia. Int. J. Oncol. 32, 387-396. doi: 10.3892/ijo.32.2.387
109. 3 results from a selective and prolonged induction of intestinal calcium-regulating genes. Endocrinology 150, 3448-3456. doi: 10.1210/en.2009-0113
110. Zhang, X., Jiang, F., Li, P., Li, C., Ma, Q., Nicosia, S. V., et al. (2005). Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin. Cancer Res. 11, 323-328.